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under the CC BY-NC-ND license (http:Abstract Background/Purpose: Autosomal dominant polycystic kidney disease (ADPKD) is
characterized by numerous epithelium-lined cysts in the kidney and is the leading genetic
cause of end-stage renal disease worldwide. Endothelin-1 is a potent vasoactive peptide impli-
cated in the regulation of basal vascular tone. Endothelin (ET)-converting enzyme 1 (ECE1) is
well known for its critical role in the process of ET.
Methods: We investigated ECE1 gene variants to unravel ECE1 modifier effects associated with
renal disease progression in ADPKD. Three ECE1 functional polymorphisms [rs213046 (839
A>C), rs213045 (338 G>T), and rs1076669 (Thr338Ile)] were genotyped using a fluorescence
resonance energy transfer-based KASPar method in 106 ADPKD patients and 112 healthy partic-
ipants. A Chi-square test was used to determine the relationship between ADPKD and ECE1 var-
iants, and multivariate logistic regression analysis was performed to assess the effect of ECE1
variants on chronic kidney disease (CKD) progression. Mantel-Haenszel stratified analysis was
performed to assess relationships between different CKD stages, hypertension, and their inter-
action.
Results: All loci are polymorphic and followed a Hardy-Weinberg equilibrium. Distribution of
ECE1 genotypes in controls and ADPKD groups was not statistically significant, and linkage
disequilibrium was not strong between pairs of single-nucleotide polymorphisms. The
rs213046 variant genotypes were overrepresented in advanced CKD stages (p Z 0.031).stitute, Chhattisgarh, Genetic Lab, Department of Biochemistry, Pandit Jawahar Lal Nehru Memorial
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ECE1 variants and CKD progression. 21Conclusion: Significant confounding effects of hypertension on CKD progression in ADPKD were
observed. These results suggested that the ECE1 gene variant is a modifier of CKD advance-
ment among ADPKD patients.
背景: 自體顯性多囊性腎病 (ADPKD) 的特點，是腎臟呈現相當多由上皮構成的囊腫，在全球是導
致末期腎病 (ESRD) 的主要遺傳性原因。Endothelin-1 (ET-1) 是一種具有高度血管活性的胜肽，
被認為與基礎血管張力的調節有關。眾所周知，endothelin (ET) 轉化酵素 1 (ECE1) 則在 ET 代
謝上佔有重要的角色。
方法: 在本研究中，我們調查了在 ADPKD 患者間，ECE1 基因變體與 CKD 病情發展的可能關聯。
我們採用以 FRET 為基礎的 KASPar 方法，對 106 位 ADPKD 患者及 112 位健康人士，作出 3 種
ECE1 功能性多態性 [rs213046 (-839 A>C)、rs213045 (-338 G>T) 及 rs1076669 (Thr338Ile)] 的
基因型辨識。對於 ADPKD 與 ECE1 基因變體的關聯，我們採取卡方檢驗；ECE1 基因變體與 CKD
病情發展的關聯，以多變項邏輯迴歸進行分析；CKD 分期與高血壓的關聯及兩者的交互作用，則
採用 Mantel-Haenszel 分層分析。
結果: 所有基因座 (loci) 均呈現多態性，且遵循 Hardy-Weinberg 平衡。ADPKD 患者與對照組間
的 ECE1 基因型分佈並無明顯差別。單核苷酸多態性鹼基對 (SNP pairs) 之間，並未呈現出明顯
的連鎖不平衡 (LD)。在晚期 CKD 患者間，rs213046 變體基因型呈現過度的表達 (p Z 0.031)。
結論: 我們觀察到，在 ADPKD 患者間，高血壓是 CKD 病情發展的一個明顯的干擾因素。以上結
果意味著，在 ADPKD 患者間，ECE1 基因變體可影響 CKD 的病情發展。Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common genetic diseases that affects
both kidneys.1 The individuals who inherit a mutated
PKD gene (PKD1, PKD2, and PKHD1) will develop renal
cysts that can be detected sonographically at 30 years of
age.2 ADPKD patients develop renal insufficiency during
the 5th decade and 6th decade of life that accounts for
w10% of all individuals requiring renal replacement
therapy. Among several renal cystic diseases, polycystic
kidney disease is the third leading cause of chronic
kidney disease (CKD) and affects 5e13.4% of patients
undergoing hemodialysis in Europe and the United
States3,4, and w3% in Eastern countries.5 The annual
incidence rate of CKD caused by ADPKD was 8.7% and 6.9
cases per million people in United States (1998-2001) and
7.8% and 6.0 per million of the population in Europe
(1998e1999).6
In ADPKD, hypertension is an early sign that occurs
even before the reduction in glomerular filtration rate.
Hence, hypertension is one of the most important factors
that influence CKD progression in ADPKD.7 Multiple lines
of evidence indicated that overactivation or dysfunction
of the endothelin (ET) system contributed to the devel-
opment and progression of hypertension and kidney dis-
ease. ET-converting enzymes (ECEs) are membrane-bound
metalloproteases that can cleave the inactive ET-1 pre-
cursor to form active ET-1 in vitro.8 ET-1 causes vaso-
constriction of renal blood vessels, resulting in decreased
renal blood flow and glomerular filtration rate.9 ECE1 and
ECE2 are two different isoforms primarily expressed in
the vascular endothelium and neural tissues, respec-
tively. The gene encoding ECE1 is located on chromosome
1p36 and consists of 20 exons spanning >120 kb.10
Alternative promoters in the gene encoding ECE1 result
in four different isoforms (ECE-1a, ECE-1b, ECE-1c, and
ECE-1d) that differ by N-terminal amino acids.11 ECE-1b isan intracellular enzyme expressed in endothelial vascular
smooth muscle cells and may contribute vascular ET-1
generation.
Variation in age and blood pressure induce ECE-1 mRNA
expression, and this finding in different segments of the
kidney has pathophysiological potential.12 Several ECE1
variants that may influence hereditary risk of cardiovascu-
lar diseases, including congenital heart disease, ischemic
stroke, and hypertension, have already been located and
examined.13e15 In view of the role of hypertension on the
progression of CKD in ADPKD, ECE1 polymorphisms are of
great interest. In this study, we investigated three impor-
tant functional ECE1 polymorphisms in order to elucidate
the modifier effects of the ECE1 gene on renal disease
progression in ADPKD.Materials and methods
Participants
This study consisted of 106 ADPKD patients confirmed
through well-established ultrasound-based criteria16 and
112 controls without any kidney-related diseases. Institu-
tional Ethics Committee approval was obtained from Sri
Ramachandra University, Chennai, India, and all patients
provided informed written consent before participating in
the study. The demographic, clinical, and biochemical var-
iables were obtained from all the participants. A Modifica-
tion of Diet in Renal Disease formula was used to determine
the glomerular filtration rate17, and the total number of
cysts were identified by ultrasound examination. The CKD
stage in all ADPKD patients was determined according to
National Kidney Foundation recommendations17, and pa-
tients were divided into two groups: preliminary stage (CKD
1e3 stages) and advanced (CKD 4 and 5 stages) stage.18
Genomic DNA from the samples was extracted by phenol
chloroformextraction and ethanol precipitation protocols.19
Table 1 Association between ECE1 variants and ADPKD
patients.
SNP ID Genotype ADPKD, n (%) Control, n (%) p*
rs213046 AA 76 (71.7) 70 (62.5)
AC 30 (28.3) 42 (37.5) 0.149
CC 0 0
MAF% 14.2 18.8
HWp 0.090 0.015
rs213045 GG 46 (43.4) 49 (43.8)
TG 47 (44.3) 47 (42.0) 0.887
TT 13 (13.3) 16 (14.3)
MAF% 34.4 35.3
HWp 0.853 0.392
rs1076669 CC 100 (94.3) 102 (91.1)
CT 6 (5.7) 8 (7.1) 0.343
TT 0 (0.0) 2 (1.8)
MAF% 2.8 5.4
HWp 0.764 0.002
* Chi-square test.
ADPKD Z autosomal dominant polycystic kidney disease;
HWp Z Hardy-Weinberg equilibrium p-value;
ID Z identification; MAF Z minor allele frequency;
SNP Z single-nucleotide polymorphism.
Figure 1 Pairwise LD measures (D0 and r2) between the
markers. Square background represents the D0/LOD values, and
the values in cells are r2 ( 100). D0 Z degree of disequilib-
rium; LD Z linkage disequilibrium; LOD Z log of the odds.
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Three ECE1 functional polymorphisms [rs213046 (839
A>C), rs213045 (338 G>T), and rs1076669 (Thr338Ile)]
were genotyped using KASPar assays, which are competitive
allele-polymerase chain reaction single-nucleotide poly-
morphism (SNP) genotyping assays using fluorescence
resonance energy transfer (FRET) quencher cassette
primers (KBioscience, Hoddesdon, UK). Amplifications were
performed in an Applied Biosystems thermocycler (ABI
Prism 9700; Applied Biosystems, Foster City, CA, USA), and
the fluorescent endpoints were measured using the 7900
SDS software (ABI Prism 7900; Applied Biosystems). The
genotyping success rate was >99.5%.
Statistical analyses
Genotypic and allelic frequencies were calculated, and
Hardy-Weinberg equilibrium (HWE) was tested. A Cochran-
Armitage trend test was used to determine the relationship
between ADPKD and ECE1 SNPs. Pairwise linkage disequi-
librium (LD) of ECE1 polymorphisms were calculated using
Haploview software version 4.1.20 To assess the effect of
ECE1 genotypes and hypertension on CKD advancement,
multivariate logistic regression analysis was performed
within the ADPKD participants. Mantel-Haenszel stratified
analysis was performed to determine the confounding ef-
fects of hypertension and family history of diabetes melli-
tus (FH-DM) on CKD progression. All statistical analyses
were carried out using SPSS version 19 (IBM Corp., Armonk,
NY, USA).
Results
A total of 106 patients with ADPKD and 112 control partic-
ipants were included in the study. The mean age of the
control group was 53.3  12.8 years and the ADPKD group
was 47.3  11.1 years. The allele and genotype frequencies
of all three polymorphisms are shown in Table 1. All poly-
morphisms followed HWE in controls. Distribution of ECE1
genotypes between the control and ADPKD groups was not
statistically significant (Table 1). Analysis of LD revealed
that there is no LD between the marker pairs, and haplo-
types were not formed. The low r2 values observed be-
tween the marker pairs was due to their low observed
heterozygosites and also the distance between the marker
pairs (rs213046 and rs213045 are separated by 0.5 kb;
rs213045 and rs1076669 are separated by w43.5 kb;
Figure 1). Among ADPKD patients, 53 (50%) showed
advanced CKD stages, with a mean age of 51.3  10.7 years,
while 53 (50%) showed moderate progression, with a mean
age of 50.1  12.9 years of age. The distribution of geno-
types between preliminary and advanced CKD groups was
statistically significant for rs213046 (pZ 0.031; Table 2). In
multivariate analysis, after adjusting for age, sex, hyper-
tension, and FH-DM, this significance vanished (p Z 0.251;
odds ration Z 1.81, 95% confidence
interval Z 0.657e4.983). The effect of hypertension and
FH-DM among different ECE1 polymorphisms revealed their
significant confounding effects on CKD progression in
ADPKD (Table 3).Discussion
Analysis of three important ECE1 polymorphisms in 106
ADPKD patients and 112 controls of South Indian origin did
not support the association between any SNP with ADPKD.
Table 2 ECE1 polymorphisms in ADPKD cases and their association with CKD stage.
Gene Genotype CKD stages Chi-square p Multivariate analysis
Preliminary stage, n (%) Advance stage, n (%) Adjusted OR (95% CI) p*
rs213046 AA 43 (81.1) 33 (62.3) 1
AC 10 (18.9) 20 (37.7) 0.031 1.81 (0.657, 4.983) 0.251
CC 0 (0) 0 (0) d
rs213045 GG 27 (50.9) 19 (35.8) 1
TG 21 (39.6) 26 (49.1) 0.270 1.53 (0.578, 4.04) 0.392
TT 5 (9.4) 8 (15.1) 1.66 (0.375, 7.327) 0.505
rs1076669 CC 52 (98.1) 48 (90.6) 1
CT 1 (1.9) 5 (9.4) 0.093 3.08 (0.28, 33.27) 0.355
TT 0 (0) 0 (0) d d
Age <40 y 22 (41.5) 9 (17.0) 1
40e60 y 27 (50.9) 35 (66.0) 0.015 5.66 (1.08, 17.79) 0.003
>60 y 4 (7.5) 9 (17.0) 14.48 (2.45, 85.52) 0.003
Sex Male 34 (64.2) 26 (49.1) 1
Female 19 (35.8) 27 (50.9) 0.117 2.05 (0.008e1.03) 0.550
HT No 39 (73.6) 47 (88.7) 1
Yes 14 (26.4) 6 (11.3) 0.047 0.29 (0.080e1.03) 0.055
FH-DM No 17 (32.1) 35 (66.0) 1
Yes 36 (67.9) 18 (34.0) <0.001 0.17 (0.06e0.46) <0.001
* Wald test p value.
ADPKD Z autosomal dominant polycystic kidney disease; CI Z confidence interval; CKD Z chronic kidney disease; FH-DM Z family
history of diabetes mellitus; HT Z hypertension; OR Z odds ratio.
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stages revealed that they were not statistically significant.
The rs213046 polymorphism showed an increase in fre-
quency of the genotype variant in advanced CKD, and the
significant confounding effects of hypertension and FH-DM
in CKD progression in ADPKD was noted.
Potentially modifiable factors affecting CKD progression
in ADPKD are the initial kidney function, proteinuria, renal
size, hypercholesterolemia, hyperuricemia, and systolic
blood pressure.21 Additionally, enhanced formation and
activity of ET-1 as a potent vasoconstrictive factor may play
a role in hypertension. Higher levels of ET were found in
low-sodium cyst fluid as compared to levels observed in
high-sodium cyst fluid, despite the fact that there is no
relationship between cyst fluid volume and ET levels in
ADPKD cases.22 Enalapril treatment resulted in increased
plasma ET concentrations and partially normalized renal
hemodynamics in borderline hypertensive ADPKD pa-
tients.23 In ADPKD and other renal diseases, few modifica-
tions in the natural balance between endothelium-derived
constricting and relaxing factors have been described.24
Furthermore, additional blockade of the endothelin type
B (ETB) receptor attenuated the effects of a sole endo-
thelin type A (ETA) receptor blockade. The ETA and ETB
receptor antagonists had no effect on blood pressure,
protein excretion, glomerular filtration rate, or kidney
morphology in Sprague-Dawley rats without renal cysts,
indicating their usefulness as an upcoming clinically used
drug for ADPKD.25 A recent study also demonstrated critical
balance between ETA and ETB activity in the cystic kidney
appears to be necessary to maintain kidney structure and
function, as well as renal disease progression in ADPKD.26
ECE-1 is the main protease responsible for ET generation
by cleavage of its functionally inactive precursor. Animportant promoter polymorphism, rs213045, is located
338 bp upstream from the transcription start site (338) of
the ECE gene. These polymorphisms results in a binding site
for the transcription factors E2F2 and GATA. The mutant
allele involving a “T” base showed increased promoter ac-
tivity as compared to wild-type allele containing a “G”
base.27 Furthermore, 338 T-allele carriers showed two-
fold higher ECE1 mRNA expression levels in the human
prefrontal cortex relative to non-carriers in vivo.28 Previous
studies demonstrated that the rs213045 variant is associ-
ated with hypertension, atherosclerosis, and ischemic
stroke.13,14 Analysis of the ECE-1b C-338A polymorphism in
different groups of Czech ADPKD patients with end-stage
renal disease did not show significant differences in the
ages with regard to different genotypes.29 Another study in
a Japanese population analyzed this mutation and found no
significant association with hypertension.30 Although 338T
was not associated with CKD progression in this study,
carriers of 839C showed progression to CKD. However,
variants containing 839G alone did not appear to affect
transcriptional activity or act synergistically with 338T to
affect transcriptional activity.27 Although ADPKD is a
monogenic disease, CKD progression in ADPKD modulated
several genetic and environmental factors. The potential
candidates clinically examined so far appear to attenuate
progression, but not to reverse already progressed renal
disease.31,32 As ET-1 acts in an autocrine and paracrine
fashion, assessment of ET-1 levels in plasma may not afford
an appropriate measure of ECE-1 activity.33 Further
research is required to clarify the association between ECE-
1 enzyme expression levels and CKD progression in ADPKD.
In conclusion, the present study demonstrated that ECE1
polymorphisms are associated with CKD progression in
ADPKD.
Table 3 Association between CKD stages and other risk
factors stratified by ECE1 genotypes.
Gene Genotype OR (95% CI) p*
Hypertension
rs213046 AA 0.095
(0.068, 0.239)
<0.001
AC 0.042
(0.011, 0.159)
CC d
M-H combined 0.074
(0.035, 0.157)
rs213045 GG 0.040
(0.009, 0.190)
<0.001
TG 0.104
(0.037, 0.288)
TT 0.050
(0.007, 0.370)
M-H combined 0.070
(0.032, 0.152)
rs1076669 CC 0.090
(0.042, 0.192)
<0.001
CT 0.167
(0.020, 0.997)
TT d
M-H combined 0.080
(0.038, 0.167)
Family history of DM
rs213046 AA 0.252
(0.096, 0.661)
0.003
AC 0.333
(0.067, 1.652)
CC d
M-H combined 0.204
(0.057, 0.726)
rs213045 GG 0.385
(0.118, 1.256)
0.002
TG 0.095
(0.037, 0.288)
TT 0.050
(0.006, 1.498)
M-H combined 0.259
(0.115, 0.588)
rs1076669 CC 0.243
(0.105, 0.559)
0.001
CT 1.500
(0.674, 0.339)
TT d
M-H combined 0.232
(0.102, 0.532)
* Homogeneity test p-value.
CI Z confidence interval; CKD Z chronic kidney disease;
DM Z diabetes mellitus; M-H Z Mantel-Haenszel; OR Z odds
ratio.
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